Well, GW Pharmaceuticals are having good results with CBD for something. Maybe they’ll have good news about schizophrenia some day too.
The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. In the United States, GW is operating as Greenwich Biosciences Inc. For further information, please visit www.gwpharm.com.